Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1

DBS is a well-established therapy for advanced Parkinson's disease, but it is unclear whether differential treatment response in PD patients may be influenced by underlying genetic mutations. Although PINK-1 is a relatively common genetic mutation associated with early-onset PD, the outcome of DBS has only been described in two patients with homozygous PINK-1 mutations so far. The patient's medical history and treatment are described, as well as the effects of DBS on their symptoms. Understanding the influence of genetic mutations on DBS outcome is important for informing prognosis and tailoring treatment. PD patients with PINK-1 mutations could be good candidates for DBS.